Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
9.70
-0.15 (-1.52%)
Mar 4, 2026, 10:15 AM EST - Market open
Relay Therapeutics Employees
Relay Therapeutics had 192 employees as of December 31, 2025. The number of employees decreased by 69 or -26.44% compared to the previous year.
Employees
192
Change
-69
Growth
-26.44%
Revenue / Employee
$79,974
Profits / Employee
-$1,439,995
Market Cap
1.73B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 192 | -69 | -26.44% |
| Sep 30, 2025 | 188 | -106 | -36.05% |
| Jun 30, 2025 | 197 | -107 | -35.20% |
| Mar 31, 2025 | 259 | -50 | -16.18% |
| Dec 31, 2024 | 261 | -62 | -19.20% |
| Sep 30, 2024 | 294 | -49 | -14.29% |
| Jun 30, 2024 | 304 | -41 | -11.88% |
| Mar 31, 2024 | 309 | -19 | -5.79% |
| Dec 31, 2023 | 323 | -4 | -1.22% |
| Sep 30, 2023 | 343 | 23 | 7.19% |
| Jun 30, 2023 | 345 | 40 | 13.11% |
| Mar 31, 2023 | 328 | 52 | 18.84% |
| Dec 31, 2022 | 327 | 82 | 33.47% |
| Sep 30, 2022 | 320 | 88 | 37.93% |
| Jun 30, 2022 | 305 | 102 | 50.25% |
| Mar 31, 2022 | 276 | 113 | 69.33% |
| Dec 31, 2021 | 245 | 86 | 54.09% |
| Sep 30, 2021 | 232 | 100 | 75.76% |
| Jun 30, 2021 | 203 | 80 | 65.04% |
| Mar 31, 2021 | 163 | 41 | 33.61% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 1,372 |
| Agios Pharmaceuticals | 540 |
| Vericel | 357 |
| Zymeworks | 263 |
| Kodiak Sciences | 123 |
| Definium Therapeutics | 74 |
| Enliven Therapeutics | 65 |
| Tyra Biosciences | 60 |
RLAY News
- 5 days ago - Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones - GlobeNewsWire
- 8 days ago - Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March - GlobeNewsWire
- 12 days ago - Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 - GlobeNewsWire
- 27 days ago - Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 4 weeks ago - Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer - GlobeNewsWire
- 5 weeks ago - Oppenheimer Upgrade Fuels Relay Therapeutics Rally On Zovegalisib Optimism - Seeking Alpha
- 2 months ago - Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 - GlobeNewsWire
- 3 months ago - Relay Therapeutics, Inc. (RLAY) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha